by Morgane De Pol | Jan 25, 2020
This article was published in Devex 20 January 2020. Opinion by Serufusa Sekidde. Despite its magnitude, lack of access to antibiotics is a largely overlooked public health issue. 5.7 million people, including 1 million children, are dying annually from...
by Morgane De Pol | Jan 25, 2020
This article was published in Health Policy Watch 16 January 2020 by Elaine Ruth Fletcher The low worldwide prices for antibiotics, combined with the need to carefully ration sale of any powerful new drugs that come to market to preserve their efficacy, continue to...
by Morgane De Pol | Jan 25, 2020
This article was published in CIDRAP 16 January 2020. A report by Chris Dall. The level of funding for late-stage research and development of new antibiotics and other products to combat antimicrobial resistance (AMR) is insufficient to meet global health needs, and...
by Morgane De Pol | Jan 25, 2020
This article was published in Science Business 16 January 2020 by Florin Zubașcu. Alarm over the rise of antimicrobial resistance has prompted an increase in early stage research and led to the discovery of a number of new antibiotics, but for the pharmaceutical...
by Morgane De Pol | Nov 26, 2019
This article was published in Pharma Boardroom on 13 November 2019. Opinion by Steve Brooks, Advisor to the AMR Industry Alliance. Steve Brooks outlines the threat that antimicrobial resistance (AMR) poses to global health, how antibiotic manufacturing may be a...
